Consumers who bought a popular cough syrup could be eligible for money as part of a class action settlement. Robitussin maker Haleon has agreed to pay $4.5 million to resolve claims it advertised the ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

The government has prohibited cough syrups containing chlorpheniramine maleate and phenylephrine hydrochloride for children ...

In March 2025, power generation rose by 4.8 percent year-on-year (YoY), reaching 8,409 GWh (11,302 MW), compared to 8,023 GWh ...

Haleon Pakistan Limited (PSX: HALEON) has decided to appoint Qawi Naseer as Chief Executive Officer of the company. The current Chief Executive Officer ...

Consumer healthcare company Haleon Pakistan Limited on Thursday named Qawi Naseer as the next Chief Executive Officer (CEO) ...

Settlement may compensate consumers who bought Robitussin cough medicine products that were falsely marketed as "non-drowsy." ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

Anyone in the U.S. who bought any flavor Robitussin product containing dextromethorphan (or DXM) and labeled as “non-drowsy” between Feb. 16, 2016, and Jan. 21 are eligible to file a claim, according ...

Archer-Daniels-Midland (ADM) has begun shutting down domestic trading operations in China and laying off staff within its largest business segment as part of ...

Haleon has gained full control of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake.

Haleon announced on Tuesday that it has agreed to acquire the remaining 12% stake in its Chinese over-the-counter joint venture, Tianjin TSKF Pharmaceutical, for CNY 1.623bn (around £200m), bringing ...